|
Real-time Estimate
Cboe BZX
22:06:44 28/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.6190 USD | -3.21% |
|
-9.65% | -60.75% |
| 09-21 | Outlook Therapeutics, Inc.(NasdaqCM:OTLK) added to S&P Global BMI Index | CI |
| 08-28 | Outlook Therapeutics, Inc. Announces CFO Changes, Effective September 1, 2026 | CI |
Company Valuation: Outlook Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 155.7 | - | - |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 230.65% | - | - |
| Enterprise Value (EV) | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 155.7 | 155.7 | 155.7 |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 230.65% | 0% | 0% |
| P/E | -6.2x | -3.94x | -0.92x | -1.32x | -0.59x | -1.1x | -2.95x | 7.11x |
| PBR | 71.9x | 29.6x | - | - | - | - | - | - |
| PEG | - | 0.3x | 0x | 0.1x | 0x | 0x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | 33.3x | 228x | 3.53x | 0.91x |
| EV / Revenue | - | - | - | - | 0x | 228x | 3.53x | 0.91x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.93x | -4.56x | 1.95x |
| EV / FCF | - | -0x | -0x | - | - | -3.99x | -14.2x | 1.15x |
| FCF Yield | - | -20.5% | -74.7% | - | - | -25.1% | -7.07% | 86.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7 | -6.2 | -4.8 | -4.06 | -1.79 | -0.58 | -0.2167 | 0.09 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 1.413 | 0.6827 | 44.07 | 170.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -51.73 | -63.07 | -53.13 | -71.7 | -67.06 | -53.11 | -34.16 | 80.01 |
| Net income 1 | -53.16 | -66.05 | -58.98 | -75.37 | -62.42 | -65.1 | -44.43 | 20.8 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 43.4000 | 24.4000 | 4.4200 | 5.3400 | 1.0600 | 0.6395 | 0.6395 | 0.6395 |
| Nbr of stocks (in thousands) | 8,767 | 11,307 | 13,012 | 23,656 | 44,420 | 243,448 | - | - |
| Announcement Date | 12/22/21 A | 12/29/22 A | 12/22/23 A | 12/27/24 A | 12/19/25 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.1x | - | - | - | 156M | |
| 33.26x | 5.97x | 17.88x | 0.98% | 47.97B | |
| 34.82x | 3.35x | 14.46x | -.--% | 44.5B | |
| -21.07x | 227.64x | -22.77x | -.--% | 43.93B | |
| 47.27x | 5.47x | 29.96x | -.--% | 41.03B | |
| 26.85x | 7.74x | 19.93x | 0.42% | 29.85B | |
| 35.19x | 5.78x | 26.24x | -.--% | 17.27B | |
| -61.04x | 9.99x | 243.78x | -.--% | 15.34B | |
| 25.79x | 2.21x | 9.6x | 1.04% | 15.3B | |
| Average | 13.33x | 33.52x | 42.38x | 0.3% | 28.37B | |
| Weighted average by Cap. | 19.68x | 43.80x | 26.11x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- OTLK Stock
- Valuation Outlook Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
